Cargando…
The effects of valbenazine on tardive dyskinesia in older and younger patients
OBJECTIVE: To evaluate the effects of once‐daily valbenazine (40 or 80 mg/d) in older and younger adults with tardive dyskinesia (TD). METHODS: Data were pooled from three 6‐week, randomized, double‐blind, placebo‐controlled (DBPC) studies (KINECT [NCT01688037], KINECT 2 [NCT01733121], and KINECT 3...
Autores principales: | Sajatovic, Martha, Alexopoulos, George S., Burke, Joshua, Farahmand, Khodayar, Siegert, Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916547/ https://www.ncbi.nlm.nih.gov/pubmed/31617235 http://dx.doi.org/10.1002/gps.5218 |
Ejemplares similares
-
A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine
por: Patel, Rikinkumar S., et al.
Publicado: (2019) -
Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient’s Perspective
por: Josiassen, Richard C., et al.
Publicado: (2017) -
Use of Valbenazine in a 54-Year-Old Female with Severe Tardive Dyskinesia
por: Yee, Maria Ruiza, et al.
Publicado: (2020) -
T7. PHARMACOGENETIC OF TARDIVE DYSKINESIA -- A FOLLOW-UP ON THE VALBENAZINE TARGET VMAT2/SLC18A2
por: Zai, Clement, et al.
Publicado: (2018) -
Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double‐blind, placebo‐controlled study (J‐KINECT)
por: Horiguchi, Jun, et al.
Publicado: (2022)